Compositions and methods for detecting Group B Streptococcus nucleic acid

A method for determining the presence or absence of a Group B Streptococcus (GBS) in a sample, said method comprising:

• (1) contacting a sample containing or suspected of containing GBS with an amplification oligomer combination comprising first CFB-factor (CFB)-specific amplification oligomer having a first hybridization sequence (A), a second CFB-specific amplification oligomer having a second hybridization sequence (B), and a CFB-specific detection probe oligomer having a second hybridization sequence (C), wherein:
• (i) (A) comprises SEQ ID NO:16, or an RNA equivalent or DNA/RNA chimeric thereof, (B) comprises SEQ ID NO:17, or an RNA equivalent or DNA/RNA chimeric thereof, and (C) is SEQ ID NO:24, or an RNA equivalent or DNA/RNA chimeric thereof;
• or
• (ii) (A) comprises SEQ ID NO:20, or an RNA equivalent or DNA/RNA chimeric thereof, (B) comprises SEQ ID NO:21, or an RNA equivalent or DNA/RNA chimeric thereof, and (C) is SEQ ID NO:25, or an RNA equivalent or DNA/RNA chimeric thereof;
• wherein the CFB-specific detection probe oligomer is about 26 to about 35 nucleotides in length and comprises a detectable label
• (2) performing an in vitro nucleic acid amplification reaction, wherein performing the in vitro nucleic acid amplification reaction comprises incubating the sample and the CFB-specific amplification oligomers under conditions suitable for amplification, wherein the target region of the GBS CFB target nucleic, if present in the sample, is amplified to generate an amplicon;
• and
• (3) analyzing the sample to detect the presence or absence of the amplicon, wherein the presence of the amplicon indicates the presence of GBS in the sample and absence of the amplicon indicates the absence of the GBS in the sample.